Departments of Proteomics & Biological Resources, ‡Antibody Engineering, and §Protein Chemistry, Genentech, Inc. , South San Francisco, California 94080, United States.
Anal Chem. 2016 Dec 20;88(24):12122-12127. doi: 10.1021/acs.analchem.6b02866. Epub 2016 Dec 8.
Bispecific antibodies, including bispecific IgG, show some promise in clinical trials as a means to extend the therapeutic potential of antibodies. Bispecific IgG can be made by separate expression and purification of each parent half antibody followed by in vitro reconstitution. Generating bispecific IgG by coexpression of two different light and heavy chains in a single host cell is potentially more efficient because it obviates the need for two separate cell lines and purification processes. However, this workflow may produce unwanted mispaired IgG species in addition to the desired bispecific IgG. Development and identification of designs that facilitate cognate light chain pairing may benefit from more refined methods to identify and quantify low levels of mispaired IgG. Using an anti-IL-4/IL-13 bispecific IgG, a mass spectrometric characterization method was developed using native or denaturing conditions by direct infusion into an Exactive Plus Extended Mass Range Orbitrap instrument. The high mass resolving power of the instrument allows unambiguous identification and accurate quantification of all light and heavy chain pairing variants in a mixture of bispecific IgG assembled in vivo upon coexpression down to 1% impurity. Preferential pairing of the anti-IL-13 light chain to its cognate heavy chain was observed, which may be leveraged to guide the design of a single-cell solution for streamlined production of bispecific IgG. Additionally, the utility of native mass spectrometry in deconvoluting complex antibody mixtures and in antigen-binding experiments to understand the contribution of doubly light chain mispaired bispecific IgG was demonstrated.
双特异性抗体,包括双特异性 IgG,在临床试验中显示出一定的应用前景,可作为扩展抗体治疗潜力的手段。双特异性 IgG 可以通过分别表达和纯化每个亲本半抗体,然后进行体外重组来制备。通过在单个宿主细胞中共表达两种不同的轻链和重链来生成双特异性 IgG 可能更有效,因为它避免了需要两个单独的细胞系和纯化过程。然而,这种工作流程除了所需的双特异性 IgG 外,还可能产生不需要的错配 IgG 物种。开发和鉴定有助于同源轻链配对的设计可能会受益于更精细的方法来识别和定量低水平的错配 IgG。使用抗 IL-4/IL-13 双特异性 IgG,通过直接注入 Exactive Plus 扩展质量范围轨道阱仪器,开发了一种使用天然或变性条件的质谱表征方法。该仪器的高质量分辨率允许在体内共表达组装的双特异性 IgG 混合物中对所有轻链和重链配对变体进行明确识别和准确定量,直至 1%的杂质。观察到抗 IL-13 轻链与其同源重链的优先配对,这可能被利用来指导单细胞溶液的设计,以简化双特异性 IgG 的生产。此外,还证明了使用天然质谱在剖析复杂抗体混合物和进行抗原结合实验以了解双重轻链错配双特异性 IgG 的贡献方面的实用性。